Mesoblast (MESO) Revenue Growth (5y) (2019 - 2023)
Mesoblast (MESO) Revenue Growth (5y) (2019 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.84 Bn | 467.05 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn |
| 10 | Mesoblast | 18.83 Bn | 18.70 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 1.76% |
| Mar 31, 2023 | 14.37% |
| Dec 31, 2022 | -18.40% |
| Sep 30, 2022 | 13.58% |
| Jun 30, 2022 | 31.48% |
| Mar 31, 2022 | 17.42% |
| Dec 31, 2021 | 52.20% |
| Sep 30, 2021 | 46.33% |
| Jun 30, 2021 | -34.37% |
| Mar 31, 2021 | -12.65% |
| Dec 31, 2020 | -9.79% |
| Sep 30, 2020 | -19.04% |
| Jun 30, 2020 | 47.94% |
| Mar 31, 2020 | -11.12% |
| Dec 31, 2019 | -12.09% |
| Sep 30, 2019 | -12.98% |